Peihua Luo

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 9

Top Topics

Plasmodium Falciparum

Tyrosine Kinase

Metastatic Colorectal Cancer

Top Venues

Nature communications

Clinical and experimental pharmacology & physiology

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Drug design, development and therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Mengting Cheng, Xinyu Tao, Fei Wang, Nonger Shen, Jiangxin Xu, Yuhuai Hu, Ping Huang, Peihua Luo, Qiaojun He, Yiwen Zhang, Fangjie Yan
Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma. Expert opinion on drug metabolism & toxicology (2024)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Zhifei Xu, Zizheng Gao, Huangxi Fu, Yan Zeng, Ying Jin, Bo Xu, Yuanteng Zhang, Zezheng Pan, Xueqin Chen, Xiaochen Zhang, Xiaohong Wang, Hao Yan, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications. Cardiovascular research (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Hao Yan, Wentong Wu, Yuhuai Hu, Jinjin Li, Jiangxin Xu, Xueqin Chen, Jiangxin Xu, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nature communications 14 (1) (2023)
Hao Yan, Xiangliang Huang, Jiangxin Xu, Ying Zhang, Jiajia Chen, Zhifei Xu, Hui Li, Zeng Wang, Xiaochun Yang, Bo Yang, Qiaojun He, Peihua Luo
Chloroquine Intervenes Nephrotoxicity of Nilotinib through Deubiquitinase USP13-Mediated Stabilization of Bcl-XL. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2023)
Yourong Zhou, Yiming Yin, Jiangxin Xu, Jiangxin Xu, Bo Yang, Qiaojun He, Peihua Luo, Hao Yan, Xiaochun Yang
An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer. Expert opinion on pharmacotherapy (2023)
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Jiangxin Xu, Xiaochun Yang
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug design, development and therapy 14 (2020)
Yi Zhu, Xiaochen Zhang, Xiaoe Lou, Min Chen, Peihua Luo, Qiaojun He
Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis. Clinical and experimental pharmacology & physiology 45 (7) (2018)